Shanghai Medicilon Inc. (SHSE:688202) shares have had a really impressive month, gaining 30% after a shaky period beforehand. Unfortunately, the gains of the last month did little to right the losses of the last year with the stock still down 14% over that time.
Although its price has surged higher, it’s still not a stretch to say that Shanghai Medicilon’s price-to-sales (or “P/S”) ratio of 4.9x right now seems quite “middle-of-the-road” compared to the Life Sciences industry in China, where the median P/S ratio is around 5.3x. Although, it’s not wise to simply ignore the P/S without explanation as investors may be disregarding a distinct opportunity or a costly mistake.
See our latest analysis for Shanghai Medicilon
How Has Shanghai Medicilon Performed Recently?
For example, consider that Shanghai Medicilon’s financial performance has been poor lately as…
